ECHA’s RAC Adopts Opinions on Classification and Labeling Proposals

The Committee for Risk Assessment (RAC) of ECHA has adopted opinions on the proposals for classification and labellng across Europe of three chemical substances as carcinogen, mutagen or toxic for reproduction The substances are:

• Indium phosphide: The classification is currently not harmonized at EU level. RAC agreed with the proposal from France that the classification of the substance should be harmonized as a carcinogen and toxic for reproduction. RAC also proposed a classification for repeated dose toxicity from inhalation exposure. Indium phosphide is, for example, used as a semiconductor in the electronics industry.

• Di-tert-butyl peroxide - DTBP: DTBP is currently classified at EU level for certain physico-chemical hazards. RAC agreed with the proposal from France to also classify it as a mutagen. DTBP is typically used by industry as an additive in polymerisation reactions.

• Trixylyl phosphate: The classification is currently not harmonised at EU level. RAC agreed with the proposal from the Netherlands for a harmonised classification of toxic for reproduction. Trixylyl phosphate is mainly used as a fire resistant hydraulic fluid, for example in industrial power generators.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences

The Start-up Platform for Chemistry & Life Sciences

The tasks range from employee protection, site security and crisis management to IT, OT and production security.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
27.03.2025 • News

Moeve Joins Global Impact Coalition

The Global Impact Coalition (GIC), a collaborative platform led by CEOs and focused on achieving a net-zero chemicals future, has announced the addition of Moeve as its newest member.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.